Skip to Content

Oncovin (vincristine) Disease Interactions

There is 1 disease interaction with Oncovin (vincristine):

Major

Vincristine (Includes Oncovin) ↔ Neurologic Dysfunction

Severe Potential Hazard, High plausibility

Applies to: Neurologic Disorder

The use of vincristine is contraindicated in patients with demyelinating conditions including Charcot-Marie-Tooth syndrome. Neurotoxicity associated with vincristine therapy is dose-related and frequently sequential. Sensorimotor (paresthesia, decreased deep- tendon reflex, ataxia, paralysis), autonomic (constipation and adynamic ileus), and CNS (mental status changes, seizures, coma) neurotoxicity have been reported. Patients with existing neuromuscular or neurologic diseases may be at increased risk for toxicity with vincristine therapy. Therapy with vincristine should be administered cautiously and dosage reduction considered in patients with neurologic dysfunction.

References

  1. Postma TJ, Benard BA, Huijgens PC, Ossenkoppele GJ, Heimans JJ "Long-term effects of vincristine on the peripheral nervous system." J Neurooncol 15 (1993): 23-7
  2. Johnson FL, Bernstein ID, Hartmann JR, Chard RL Jr "Seizures associated with vincristine sulfate therapy." J Pediatr 82 (1973): 699-702
  3. Weiden PL, Wright SE "Vincristine neurotoxicity." N Engl J Med 286 (1972): 1369-70
  4. Watkins SM, Griffin JP "High incidence of vincristine-induced neuropathy in lymphomas." Br Med J 1 (1978): 610-2
  5. Jalihal S, Roebuck N "Acute vincristine neurotoxicity." Lancet 1 (1985): 637
  6. Rosenthal S, Kaufman S "Vincristine neurotoxicity." Ann Intern Med 80 (1974): 733-7
  7. Delaney P "Vincristine-induced laryngeal nerve paralysis." Neurology 32 (1982): 1285-8
  8. "Product Information. Oncovin (vincristine)." Lilly, Eli and Company, Indianapolis, IN.
  9. Tormey DC "Neurotoxicity of vincristine." Lancet 1 (1973): 1312
  10. Martin J, Mainwaring D "Letter: Coma and convulsions associated with vincristine therapy." Br Med J 4 (1973): 782-3
  11. Warrier RP, Tan T, Patel Y, Yu LC, Quarls K, Shenoy S "Vincristine neurotoxicity." Indian Pediatr 29 (1992): 370-3
  12. Annino DJ Jr, MacArthur CJ, Friedman EM "Vincristine-induced recurrent laryngeal nerve paralysis." Laryngoscope 102 (1992): 1260-2
View all 12 references

Oncovin (vincristine) drug Interactions

There are 391 drug interactions with Oncovin (vincristine)

Drug Interaction Classification

The classifications below are a general guideline only. It is difficult to determine the relevance of a particular drug interaction to any individual given the large number of variables.
Major Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit.
Moderate Moderately clinically significant. Usually avoid combinations; use it only under special circumstances.
Minor Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan.
Unknown No information available.

Do not stop taking any medications without consulting your healthcare provider.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Hide